STOCK TITAN
  1. Home
  2. News
  3. TGTX

TG Therapeutics Inc - TGTX STOCK NEWS

Welcome to our dedicated news page for TG Therapeutics (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on TG Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TG Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TG Therapeutics's position in the market.

News
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Rhea-AI Summary
TG Therapeutics presents data from Phase 3 trials of BRIUMVI at ECTRIMS annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
-
News
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Rhea-AI Summary
TG Therapeutics announces data presentations at the 2023 ECTRIMS annual meeting for BRIUMVI® in patients with relapsing forms of multiple sclerosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
-
News
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
TG Therapeutics CEO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
News
TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
TG Therapeutics CEO to participate in fireside chat at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences
-
News
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
TG Therapeutics, Inc. (NASDAQ: TGTX) reported second quarter 2023 financial results, with net sales of $16 million in the United States and total net revenue of approximately $24 million since the launch of BRIUMVI. Over 1,200 BRIUMVI prescriptions have been made by 340+ healthcare providers at 225+ centers across the U.S. Payor coverage is in place for about 80% of covered lives. The company also announced an agreement with Neuraxpharm for the ex-U.S. commercialization of BRIUMVI in RMS, strengthening its balance sheet with a pro-forma cash balance of approximately $285 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.3%
Tags
earnings
-
News
TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
Rhea-AI Summary
TG Therapeutics and Neuraxpharm announce an agreement for the ex-US commercialization of BRIUMVI, the first and only anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis. Neuraxpharm will launch BRIUMVI in Europe within the next six months, and TG retains the option to buy back all rights under the agreement if TG is acquired. TG Therapeutics will receive an upfront payment of $140 million and is eligible for up to $492.5 million in milestone-based payments. TG will also receive tiered double-digit royalties on net product sales up to 30%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.3%
Tags
none
News
TG Therapeutics to Host Conference Call on Second Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
TG Therapeutics, Inc. (NASDAQ: TGTX) will hold a conference call on August 1, 2023, at 8:30 AM ET to discuss second quarter 2023 results and provide a business outlook. Chairman and CEO, Michael S. Weiss, will host the call. Participants can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) with the conference title 'TG Therapeutics.' A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days after the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.03%
Tags
conferences earnings
-
News
TG Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
Rhea-AI Summary
TG Therapeutics CEO to participate in fireside chat at Jefferies Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
conferences
-
News
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
clinical trial
News
TG Therapeutics Announces European Commission Approval for BRIUMVI® (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
none
Stock TGTX logo
TG Therapeutics Inc

Nasdaq:TGTX

TGTX Rankings

#1813 Ranked by Market Cap
#924 Ranked by Stock Gains
N/A Ranked by Dividends

TGTX Stock Data

2.19B
134.88M
9.08%
59.26%
22.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About TGTX

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".